ABSTRACT
The most common form of neurologic injury in sickle cell anemia (SCA) is silent cerebral infarction (SCI). In the Silent Cerebral Infarct Multi-Center Clinical Trial, we sought to identify risk factors associated with SCI. In this cross-sectional study, we evaluated the clinical history and baseline laboratory values and performed magnetic resonance imaging of the brain in participants with SCA (HbSS or HbSß° thalassemia) between the ages of 5 and 15 years with no history of overt stroke or seizures. Neuroradiology and neurology committees adjudicated the presence of SCI. SCIs were diagnosed in 30.8% (251 of 814) participants who completed all evaluations and had valid data on all prespecified demographic and clinical covariates. The mean age of the participants was 9.1 years, with 413 males (50.7%). In a multivariable logistic regression analysis, lower baseline hemoglobin concentration (P < .001), higher baseline systolic blood pressure (P = .018), and male sex (P = .030) were statistically significantly associated with an increased risk of an SCI. Hemoglobin concentration and systolic blood pressure are risk factors for SCI in children with SCA and may be therapeutic targets for decreasing the risk of SCI. This study is registered at www.clinicaltrials.gov as #NCT00072761.
Subject(s)
Anemia, Sickle Cell/epidemiology , Anemia, Sickle Cell/therapy , Blood Pressure , Blood Transfusion , Cerebral Infarction/epidemiology , beta-Thalassemia/epidemiology , Adolescent , Anemia, Sickle Cell/blood , Asymptomatic Diseases/epidemiology , Cerebral Infarction/blood , Cerebral Infarction/pathology , Child , Child, Preschool , Cross-Sectional Studies , Female , Hemoglobin, Sickle/metabolism , Humans , Magnetic Resonance Imaging , Male , Multivariate Analysis , Risk Factors , Sex Distribution , beta-Thalassemia/bloodABSTRACT
BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p = 0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses.
Subject(s)
Blood Coagulation Factors/adverse effects , Hemophilia A , Parvoviridae Infections/blood , Parvoviridae Infections/transmission , Parvovirus B19, Human/isolation & purification , Algorithms , Blood Banking/methods , Blood Coagulation Factors/therapeutic use , Child , Child, Preschool , Communicable Diseases, Emerging/blood , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/transmission , DNA, Viral/analysis , Female , Hemophilia A/blood , Hemophilia A/drug therapy , Hemophilia A/virology , Hemorrhage/blood , Hemorrhage/drug therapy , Hemorrhage/virology , Humans , Infection Control/methods , Logistic Models , Male , Parvoviridae Infections/epidemiology , Parvovirus B19, Human/genetics , Prevalence , Seroepidemiologic StudiesABSTRACT
INTRODUCTION: Quality-of-life (QOL) assessments in frequently bleeding patients with congenital hemophilia with inhibitors and their families are confounded by preexisting arthropathy and family circumstances. Periodic QOL assessments typically made on nonbleed days may not provide complete reflections of the burden on patients/families. AIM: To evaluate the impact of bleeding episodes on patients/caregivers/families and the association between monthly QOL scores and patients' average diary experiences. METHODS: Frequently bleeding inhibitor patients (≥four bleeds in 3 months), or their caregivers, provided daily assessment of EuroQol five-dimensional questionnaire and EuroQol five-dimensional questionnaire visual analogue scale, pain (11-point Likert scale), and family anxiety/stress/activity change over 3 to 6 months. QOL scores were stratified by bleed/nonbleed days. RESULTS: Patient QOL assessments were recorded by 37 of the 39 enrolled patients/caregivers (3771 of 3777 eligible dairy days, 472 bleed/3299 nonbleed days). Median (range) diary duration was 91 (66-180) days, with 8.2% (0%-72.2%) bleed days. Mean health scores were significantly worse on bleed days than on nonbleed days (P < 0.0001 for all): EuroQol five-dimensional questionnaire index, 0.66 versus 0.82; visual analogue scale health, 69.7 versus 77.4; and pain score, 4.1 versus 1.8. Bleed days also had higher (P < 0.001) proportions of days with abnormalities in family anxiety/stress (42% vs. 30%) and family activity changes (34% vs. 21%). CONCLUSIONS: Assessing the impact of hemophilia with inhibitors on patient/family QOL typically includes periodic (likely nonbleed day) evaluations reflecting baseline abnormalities. Daily assessment, however, indicated that frequent acute bleeds impair QOL beyond patient's nonbleed day baseline. New approaches are required to assess the cumulative impact of frequent acute bleeds on patients and their families.
Subject(s)
Family/psychology , Hemophilia A/immunology , Hemophilia A/physiopathology , Hemorrhage/psychology , Isoantibodies/metabolism , Quality of Life/psychology , Acute Disease , Adolescent , Adult , Child , Child, Preschool , Humans , Infant , Male , Middle Aged , Qualitative Research , Surveys and Questionnaires , United States , Young AdultABSTRACT
The occurrence of multiple abnormalities of α, ß, δ, and γ globin genes may lead to unusual and complex phenotypes when they arise simultaneously in the same individual. Here, we report the findings of an African American boy who coinherited 3 heterozygous globin gene abnormalities: the unstable ß-globin chain variant; hemoglobin (Hb) Showa-Yakushiji [ß110(G12) LeuâPro], the δ-globin chain variant; HbB2 [δ16(A13) GlyâArg] and α-thalassemia (α-thal); (α-/αα). Hb Showa-Yakushiji had been previously described in Japanese, Indian, and European populations. We report its first occurrence in a child of African ancestry who presented with anemia not responsive to iron and an incomplete ß-thalassemia minor phenotype. Although the clinical and laboratory features of Hb Showa-Yakushiji mimic those of a ß-thalassemia, the coinheritance of the δ-globin chain variant Hb B2 suppressed the relative increase in Hb A2 usually observed in heterozygotes for the Hb Showa-Yakushiji mutation. Protein-based methods detected only a trace amount of HbB2 and failed to reveal presence of Hb Showa-Yakushiji and α-thal. The latter were only identified through DNA analyses. The diagnostic difficulties, molecular characteristics, and genotype/phenotype correlations of this novel complex hemoglobinopathy syndrome are reviewed.
Subject(s)
Anemia/genetics , Hemoglobins, Abnormal/genetics , alpha-Thalassemia/genetics , beta-Thalassemia/genetics , delta-Thalassemia/genetics , Black or African American/genetics , Anemia/etiology , Child, Preschool , Heterozygote , Humans , Male , Phenotype , alpha-Thalassemia/blood , alpha-Thalassemia/complications , beta-Thalassemia/blood , beta-Thalassemia/complications , delta-Thalassemia/complicationsABSTRACT
Hemolysis contributes to the pathology associated with sickle cell disease. However, the mechanism of hemolysis or relative contribution of sickling due to hemoglobin (Hb) polymerization vs. oxidative damage remains unknown. Earlier studies aimed at deciphering the relative importance of these two mechanisms have been complicated by the fact that sickle red cells (SS) have already been affected by multiple rounds of sickling and oxidative damage before they are collected. In our study, we examine the mechanical fragility of sickle cell trait cells, which do not sickle in vivo, but can be made to do so in vitro. Thus, our novel approach explores the effects of sickle Hb polymerization on cells that have never been sickled before. We find that the mechanical fragility of these cells increases dramatically after a single sickling event, suggesting that a substantial amount of hemolysis in vivo probably occurs in polymer-containing cells.
Subject(s)
Erythrocytes/pathology , Sickle Cell Trait/blood , Sickle Cell Trait/pathology , Hemoglobin, Sickle/analysis , Hemoglobin, Sickle/metabolism , Hemolysis , HumansABSTRACT
BACKGROUND: By the age of 20 years, 10% of sickle cell disease (SCD) patients have experienced a stroke. It is unclear if SCD stroke is due primarily to hemodynamic effects of intracranial stenosis, or metabolic failure from anemia. Transcranial Doppler ultrasound (TCD) identifies a SCD subgroup with high stroke risk, but high mean flow velocity (MFV) can be due to stenosis or high flow rate, as with metabolic hyperemia of severe anemia. Dynamic Vascular Analysis (DVA; New Health Sciences, Inc., Bethesda, MD) is a new way to analyze TCD data, with potential to separate structural from metabolic causes of high MFV. METHODS: Eighty SCD patients, regardless of hemoglobin genotypes, aged 2 to 22 years, without clinical stroke or transient ischemic attack (TIA), who had TCD (1/1/02 to 1/1/04) as part of routine outpatient clinical follow-up, with both the TCD report and study videotape available, were included. Waveforms were reviewed and marked by protocol, and DVA indices calculated including MFV, pulsatility index (PI), systolic acceleration (SA), dynamic flow index (DFI), dynamic pressure index (DPI), and dynamic compliance index (DCI). Mean and standard deviation were defined for the whole group, and for four subgroups, by age. RESULTS: MFV, DFI, and DPI were highest at 6- to 9-year-olds, declining thereafter. The 14- to 22-year-old group was also compared to a group of healthy young athletes (15- to 22 years old). SCD patients had higher MFV, lnSA, DFI, DPI, and lower PI and DCI in most segments, suggesting global hyperemia. CONCLUSION: This is the first report of cross-sectional results of DVA in a cohort of SCD outpatients without prior clinical stroke (TIA). These results suggest hyperemia without significant focal intracranial stenosis. There were also differences between asymptomatic SCD and young athletes, and the MFV, DFI, and DPI were highest at the age of 6 to 9 years, decreasing as age increased.
Subject(s)
Anemia, Sickle Cell/physiopathology , Blood Flow Velocity , Cerebrovascular Circulation , Hyperemia , Adolescent , Adult , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/diagnostic imaging , Child , Child, Preschool , Female , Humans , Male , Stroke/etiology , Ultrasonography, Doppler, TranscranialABSTRACT
BACKGROUND: Relative to hemoglobin A(1c) (HbA(1c)), percentage of glycated albumin (GA%) more accurately reflects recent glycemic control in diabetic hemodialysis (HD) patients. METHODS: To determine the accuracy of glycemic assays in a larger sample including patients on peritoneal dialysis (PD), HbA(1c) and GA% were measured in 519 diabetic subjects: 55 on PD, 415 on HD, and 49 non-nephropathy controls. RESULTS: Mean +/- SD serum glucose levels were higher in HD and PD patients relative to non-nephropathy controls (HD 169.7 +/- 62 mg/dL, PD 168.6 +/- 66 mg/dL, controls 146.1 +/- 66 mg/dL; p = 0.03 HD vs controls, p = 0.13 PD vs controls). GA% was also higher in HD and PD patients (HD 20.6% +/- 8.0%, PD 19.0% +/- 5.7%, controls 15.7% +/- 7.7%; p < 0.02 HD vs controls and PD vs controls). HbA(1c) was paradoxically lower in dialysis patients (HD 6.78% +/- 1.6%, PD 6.87% +/- 1.4%, controls 7.3% +/- 1.4%; p = 0.03 HD vs controls, p = 0.12 PD vs controls). The serum glucose/HbA(1c) ratio differed significantly between dialysis patients and controls (p < 0.0001 HD vs controls, p = 0.002 PD vs controls), while serum glucose/GA% ratio was similar across groups (p = 0.96 HD vs controls, p = 0.64 PD vs controls). In best-fit multivariate models with HbA(1c) or GA% as outcome variable, dialysis status was a significant predictor of HbA(1c) but not GA%. CONCLUSIONS: The relationship between HbA(1c) and GA% differs in diabetic patients with end-stage renal disease who perform either PD or HD compared to those without nephropathy. HbA(1c) significantly underestimates glycemic control in peritoneal and hemodialysis patients relative to GA%.
Subject(s)
Diabetes Mellitus/blood , Glycated Hemoglobin/analysis , Renal Dialysis , Serum Albumin/analysis , Diabetes Complications/blood , Female , Glycation End Products, Advanced , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Male , Middle Aged , Peritoneal Dialysis , Glycated Serum AlbuminABSTRACT
A rapid ( approximately 90 sec), fully automated method is described for quantifying hemoglobin S (HbS) by high performance liquid chromatography (HPLC) using the Bio-Rad Variant II Turbo analyzer. Although this instrument is designed to quantify only blood hemoglobin A1c (HbA1c), we show that it can also quantify accurately, without modification, HbS levels in sickle cell patients, provided the blood samples meet certain conditions. The samples should contain detectable hemoglobin F (HbF), but should not contain hemoglobin C (HbC). Under these conditions, blood HbS levels obtained by this method correlate well with those obtained by agarose electrophoresis (r(2) = 0.97, n = 81 patients). We also show that quantitation of blood HbF in sickle cell patients is more accurate by this method than by agarose electrophoresis when the HbF level is in the range from 0.2 to 10%.